知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.028 秒)

    ANTI-LIPOARABINOMANNAN ANTIBODY AND IMMUNOASSAY FOR ACID-FAST BACILLARY INFECTION USING THE ANTIBODY
    1.
    发明申请
    ANTI-LIPOARABINOMANNAN ANTIBODY AND IMMUNOASSAY FOR ACID-FAST BACILLARY INFECTION USING THE ANTIBODY 有权
    抗紫杉醇胺抗体和免疫应答使用抗体进行急性乙肝感染

    公开(公告)号：US20160083458A1

    公开(公告)日：2016-03-24

    申请号：US14378922

    申请日：2013-02-28

    申请人： OTSUKA PHARMACEUTICAL CO., LTD

    发明人： Kiyonori KATSURAGI ,  Masataka TOGASHI ,  Tetsuya ODA ,  Ryuta ITO ,  Chie KAWAGUCHI ,  Yoko SAIJO ,  Daisuke KOGA ,  Makoto MATSUMOTO ,  Mamoru FUJIWARA ,  Kenji ONO

    IPC分类号： C07K16/12 ,  G01N33/569 ,  C07K16/00

    CPC分类号： C07K16/1285 ,  C07K16/005 ,  C07K16/1289 ,  C07K2317/35 ,  C07K2317/622 ,  G01N33/5695 ,  G01N2333/35 ,  G01N2400/50

    摘要： The present invention provides a monoclonal antibody that specifically binds to acid-fast bacillary lipoarabinomannan, particularly tubercle bacillary lipoarabinomannan, the antibody being set forth below: (A) a monoclonal antibody comprising a heavy chain variable region and a light chain variable region joined via a linker, the heavy chain variable region comprising heavy chains CDR1 to CDR3 shown in (a) to (c) below, and the light chain variable region comprising light chains CDR1 to CDR3 shown in (d) to (f) below: (a) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 1, (b) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 2, (c) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 3, (d) light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 4, (e) light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 5, and (f) light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 6. The present invention further provides the use of the antibody.

    摘要翻译： 本发明提供了一种特异性结合耐酸杆菌性脂肪阿拉伯甘露聚糖，特别是结核杆菌脂褐素甘露聚糖的单克隆抗体，该抗体如下：（A）包含重链可变区和轻链可变区的单克隆抗体， 接头，包含下文（a）至（c）所示的重链CDR1至CDR3的重链可变区和包含以下（d）至（f）所示的轻链CDR1至CDR3的轻链可变区：（a） 由SEQ ID NO：1所示的氨基酸序列组成的重链CDR1，（b）由SEQ ID NO：2所示的氨基酸序列组成的重链CDR1，（c）由氨基酸组成的重链CDR1 SEQ ID NO：3所示的序列，（d）由SEQ ID NO：4所示的氨基酸序列组成的轻链CDR1，（e）由SEQ ID NO：3所示的氨基酸序列组成的轻链CDR1， 5，和（f）由ami组成的轻链CDR1 没有SEQ ID NO：6所示的酸序列。本发明还提供了抗体的用途。